Design, Synthesis, and Evaluation of Novel and Selective G‑protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists

Type 2 diabetes mellitus (T2DM) is an ever increasing worldwide epidemic, and the identification of safe and effective insulin sensitizers, absent of weight gain, has been a long-standing goal of diabetes research. G-protein coupled receptor 120 (GPR120) has recently emerged as a potential therapeut...

Full description

Saved in:
Bibliographic Details
Published in:ACS medicinal chemistry letters 2017-01, Vol.8 (1), p.49-54
Main Authors: Cox, Jason M, Chu, Hong D, Chelliah, Mariappan V, Debenham, John S, Eagen, Keith, Lan, Ping, Lombardo, Matthew, London, Clare, Plotkin, Michael A, Shah, Unmesh, Sun, Zhongxiang, Vaccaro, Henry M, Venkatraman, Srikanth, Suzuki, Takao, Wang, Nengxue, Ashley, Eric R, Crespo, Alejandro, Madeira, Maria, Leung, Dennis H, Alleyne, Candice, Ogawa, Aimie M, Souza, Sarah, Thomas-Fowlkes, Brande, Di Salvo, Jerry, Weinglass, Adam, Kirkland, Melissa, Pachanski, Michele, Powles, Mary Ann, Tozzo, Effie, Akiyama, Taro E, Ujjainwalla, Feroze, Tata, James R, Sinz, Christopher J
Format: Article
Language:English
Subjects:
Letter
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes mellitus (T2DM) is an ever increasing worldwide epidemic, and the identification of safe and effective insulin sensitizers, absent of weight gain, has been a long-standing goal of diabetes research. G-protein coupled receptor 120 (GPR120) has recently emerged as a potential therapeutic target for treating T2DM. Natural occurring, and more recently, synthetic agonists have been associated with insulin sensitizing, anti-inflammatory, and fat metabolism effects. Herein we describe the design, synthesis, and evaluation of a novel spirocyclic GPR120 agonist series, which culminated in the discovery of potent and selective agonist 14. Furthermore, compound 14 was evaluated in vivo and demonstrated acute glucose lowering in an oral glucose tolerance test (oGTT), as well as improvements in homeostatic measurement assessment of insulin resistance (HOMA-IR; a surrogate marker for insulin sensitization) and an increase in glucose infusion rate (GIR) during a hyperinsulinemic euglycemic clamp in diet-induced obese (DIO) mice.
ISSN:1948-5875
1948-5875
DOI:10.1021/acsmedchemlett.6b00360